Do analysts recommend OBSV or ELAB?

Given ObsEva's higher probable upside, equities analysts plainly believe ObsEva is more favorable than PMGC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, OBSV or ELAB?

PMGC has higher revenue and earnings than ObsEva. PMGC is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A PMGC $590K 3.31 -$7.75M -$168.62 N/A

Is OBSV or ELAB more profitable?

PMGC's return on equity of -117.82% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% PMGC N/A -117.82% -70.79%

Do analysts rate LNAI or ELAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, LNAI or ELAB?

PMGC has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A PMGC $590K 3.31 -$7.75M -$168.62 N/A

Is LNAI or ELAB more profitable?

PMGC's return on equity of -117.82% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% PMGC N/A -117.82% -70.79%

Do analysts prefer ELAB or GRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ELAB or GRTX more profitable?

Galera Therapeutics' return on equity of 0.00% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% Galera Therapeutics N/A N/A -99.34%

Do analysts recommend ENVB or ELAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ENVB or ELAB more profitable?

PMGC's return on equity of -117.82% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -220.97% -177.47% PMGC N/A -117.82% -70.79%

Does the media refer more to ENVB or ELAB?

In the previous week, PMGC had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 4 mentions for PMGC and 1 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.96 beat PMGC's score of 0.49 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PMGC 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NKGN or ELAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, NKGN or ELAB?

PMGC has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.51 N/A PMGC $590K 3.31 -$7.75M -$168.62 N/A

Is NKGN or ELAB more profitable?

NKGen Biotech's return on equity of 0.00% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% PMGC N/A -117.82% -70.79%

Does the media refer more to NKGN or ELAB?

In the previous week, PMGC had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for PMGC and 1 mentions for NKGen Biotech. PMGC's average media sentiment score of 0.49 beat NKGen Biotech's score of 0.00 indicating that PMGC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NKGen Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PMGC 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PMGC (ELAB) Competitors

$1.68 -0.13 (-6.91%)

As of 02:29 PM Eastern

Compare

ELAB vs. OBSV, LNAI, GRTX, ENVB, and NKGN

Should you buy PMGC stock or one of its competitors? MarketBeat compares PMGC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PMGC include ObsEva (OBSV), Lunai Bioworks (LNAI), Galera Therapeutics (GRTX), Enveric Biosciences (ENVB), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry.

How does PMGC compare to ObsEva?

ObsEva (NASDAQ:OBSV) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, PMGC has a beta of -0.27, suggesting that its stock price is 127% less volatile than the broader market.

PMGC's return on equity of -117.82% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
PMGC	N/A	-117.82%	-70.79%

PMGC has higher revenue and earnings than ObsEva. PMGC is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
PMGC	$590K	3.31	-$7.75M	-$168.62	N/A

Given ObsEva's higher probable upside, equities analysts plainly believe ObsEva is more favorable than PMGC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 0.0% of PMGC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, PMGC had 4 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for PMGC and 0 mentions for ObsEva. PMGC's average media sentiment score of 0.49 beat ObsEva's score of 0.00 indicating that PMGC is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
PMGC	Neutral

Summary

PMGC beats ObsEva on 8 of the 13 factors compared between the two stocks.

How does PMGC compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Lunai Bioworks has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, PMGC has a beta of -0.27, meaning that its share price is 127% less volatile than the broader market.

In the previous week, PMGC had 4 more articles in the media than Lunai Bioworks. MarketBeat recorded 4 mentions for PMGC and 0 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 0.62 beat PMGC's score of 0.49 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
PMGC	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 0.0% of PMGC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PMGC's return on equity of -117.82% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
PMGC	N/A	-117.82%	-70.79%

PMGC has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
PMGC	$590K	3.31	-$7.75M	-$168.62	N/A

Summary

PMGC beats Lunai Bioworks on 6 of the 11 factors compared between the two stocks.

How does PMGC compare to Galera Therapeutics?

PMGC (NASDAQ:ELAB) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Galera Therapeutics' return on equity of 0.00% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
Galera Therapeutics	N/A	N/A	-99.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

22.2% of PMGC shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 0.0% of PMGC shares are owned by insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PMGC has higher revenue and earnings than Galera Therapeutics. PMGC is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$590K	3.31	-$7.75M	-$168.62	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16

In the previous week, PMGC had 4 more articles in the media than Galera Therapeutics. MarketBeat recorded 4 mentions for PMGC and 0 mentions for Galera Therapeutics. PMGC's average media sentiment score of 0.49 beat Galera Therapeutics' score of 0.00 indicating that PMGC is being referred to more favorably in the media.

Company	Overall Sentiment
PMGC	Neutral
Galera Therapeutics	Neutral

PMGC has a beta of -0.27, suggesting that its share price is 127% less volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.64, suggesting that its share price is 164% more volatile than the broader market.

Summary

PMGC beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.

How does PMGC compare to Enveric Biosciences?

Enveric Biosciences (NASDAQ:ENVB) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

PMGC's return on equity of -117.82% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
PMGC	N/A	-117.82%	-70.79%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 0.0% of PMGC shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, PMGC had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 4 mentions for PMGC and 1 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.96 beat PMGC's score of 0.49 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PMGC	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enveric Biosciences has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, PMGC has a beta of -0.27, suggesting that its stock price is 127% less volatile than the broader market.

PMGC has higher revenue and earnings than Enveric Biosciences. Enveric Biosciences is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
PMGC	$590K	3.31	-$7.75M	-$168.62	N/A

Summary

PMGC beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks.

How does PMGC compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, PMGC had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for PMGC and 1 mentions for NKGen Biotech. PMGC's average media sentiment score of 0.49 beat NKGen Biotech's score of 0.00 indicating that PMGC is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NKGen Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PMGC	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NKGen Biotech has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, PMGC has a beta of -0.27, suggesting that its stock price is 127% less volatile than the broader market.

PMGC has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A
PMGC	$590K	3.31	-$7.75M	-$168.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NKGen Biotech's return on equity of 0.00% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
PMGC	N/A	-117.82%	-70.79%

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 22.2% of PMGC shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 0.0% of PMGC shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

PMGC beats NKGen Biotech on 7 of the 12 factors compared between the two stocks.

Get PMGC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELAB vs. The Competition

Export

Metric	PMGC	DIVERSIFIED OPS Industry	Multi-Sector Sector	NASDAQ Exchange
Market Cap	$1.96M	$19.84B	$18.14B	$12.48B
Dividend Yield	N/A	4.15%	3.91%	5.22%
P/E Ratio	-0.01	29.68	24.82	24.39
Price / Sales	3.31	8.21	6.95	116.29
Price / Cash	N/A	52.30	49.81	57.13
Price / Book	0.02	4.52	4.00	6.74
Net Income	-$7.75M	$930.27M	$920.86M	$337.03M
7 Day Performance	-12.24%	-2.27%	-1.99%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-99.09%	21.76%	19.15%	34.29%

PMGC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELAB PMGC	0.2357 of 5 stars	$1.69 -6.9%	N/A	-99.0%	$1.96M	$590K	N/A	18	Short Interest Increase
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
LNAI Lunai Bioworks	0.2216 of 5 stars	$2.62 +24.2%	N/A	N/A	$7.92M	$20.94K	N/A	20
GRTX Galera Therapeutics	N/A	$0.10 +4.8%	N/A	+286.1%	$7.91M	N/A	N/A	30
ENVB Enveric Biosciences	1.1101 of 5 stars	$2.14 -4.0%	N/A	-87.0%	$7.88M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELAB) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMGC (ELAB) Competitors